196 related articles for article (PubMed ID: 31578248)
1. Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027.
Peng Z; Simeon R; Mitchell SB; Zhang J; Feng H; Chen Z
mSphere; 2019 Oct; 4(5):. PubMed ID: 31578248
[No Abstract] [Full Text] [Related]
2. Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B.
Simeon R; Jiang M; Chamoun-Emanuelli AM; Yu H; Zhang Y; Meng R; Peng Z; Jakana J; Zhang J; Feng H; Chen Z
PLoS Biol; 2019 Jun; 17(6):e3000311. PubMed ID: 31233493
[TBL] [Abstract][Full Text] [Related]
3. Functional defects in
Gupta P; Zhang Z; Sugiman-Marangos SN; Tam J; Raman S; Julien JP; Kroh HK; Lacy DB; Murgolo N; Bekkari K; Therien AG; Hernandez LD; Melnyk RA
J Biol Chem; 2017 Oct; 292(42):17290-17301. PubMed ID: 28842504
[No Abstract] [Full Text] [Related]
4. Receptor Binding Domains of TcdB from
Henkel D; Tatge H; Schöttelndreier D; Tao L; Dong M; Gerhard R
Toxins (Basel); 2020 Nov; 12(12):. PubMed ID: 33255261
[TBL] [Abstract][Full Text] [Related]
5. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production.
Merrigan M; Venugopal A; Mallozzi M; Roxas B; Viswanathan VK; Johnson S; Gerding DN; Vedantam G
J Bacteriol; 2010 Oct; 192(19):4904-11. PubMed ID: 20675495
[TBL] [Abstract][Full Text] [Related]
6. Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.
Maynard-Smith M; Ahern H; McGlashan J; Nugent P; Ling R; Denton H; Coxon R; Landon J; Roberts A; Shone C
Vaccine; 2014 Feb; 32(6):700-5. PubMed ID: 24342251
[TBL] [Abstract][Full Text] [Related]
7. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of BI/NAP1/027 hypervirulent strains reveals novel toxin B-encoding gene (tcdB) sequences.
Stabler RA; Dawson LF; Phua LTH; Wren BW
J Med Microbiol; 2008 Jun; 57(Pt 6):771-775. PubMed ID: 18480336
[TBL] [Abstract][Full Text] [Related]
9. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.
Hirota SA; Iablokov V; Tulk SE; Schenck LP; Becker H; Nguyen J; Al Bashir S; Dingle TC; Laing A; Liu J; Li Y; Bolstad J; Mulvey GL; Armstrong GD; MacNaughton WK; Muruve DA; MacDonald JA; Beck PL
Infect Immun; 2012 Dec; 80(12):4474-84. PubMed ID: 23045481
[TBL] [Abstract][Full Text] [Related]
10. Genomic and Phenotypic Characterization of the Nontoxigenic Clostridioides difficile Strain CCUG37785 and Demonstration of Its Therapeutic Potential for the Prevention of C. difficile Infection.
Wang S; Heuler J; Wickramage I; Sun X
Microbiol Spectr; 2022 Apr; 10(2):e0178821. PubMed ID: 35315695
[TBL] [Abstract][Full Text] [Related]
11. Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.
Carter GP; Chakravorty A; Pham Nguyen TA; Mileto S; Schreiber F; Li L; Howarth P; Clare S; Cunningham B; Sambol SP; Cheknis A; Figueroa I; Johnson S; Gerding D; Rood JI; Dougan G; Lawley TD; Lyras D
mBio; 2015 Jun; 6(3):e00551. PubMed ID: 26037121
[TBL] [Abstract][Full Text] [Related]
12. Expression and (Lacking) Internalization of the Cell Surface Receptors of
Schöttelndreier D; Seeger K; Grassl GA; Winny MR; Lindner R; Genth H
Front Microbiol; 2018; 9():1483. PubMed ID: 30022975
[TBL] [Abstract][Full Text] [Related]
13. Sequence variation in tcdA and tcdB of Clostridium difficile: ST37 with truncated tcdA is a potential epidemic strain in China.
Du P; Cao B; Wang J; Li W; Jia H; Zhang W; Lu J; Li Z; Yu H; Chen C; Cheng Y
J Clin Microbiol; 2014 Sep; 52(9):3264-70. PubMed ID: 24958798
[TBL] [Abstract][Full Text] [Related]
14. Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection.
Wang S; Zhu D; Sun X
Microbiol Spectr; 2022 Jun; 10(3):e0026322. PubMed ID: 35583336
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection.
Chen P; Zeng J; Liu Z; Thaker H; Wang S; Tian S; Zhang J; Tao L; Gutierrez CB; Xing L; Gerhard R; Huang L; Dong M; Jin R
Nat Commun; 2021 Jun; 12(1):3748. PubMed ID: 34145250
[TBL] [Abstract][Full Text] [Related]
16. Protease-stable DARPins as promising oral therapeutics.
Simeon RA; Zeng Y; Chonira V; Aguirre AM; Lasagna M; Baloh M; Sorg JA; Tommos C; Chen Z
Protein Eng Des Sel; 2021 Feb; 34():. PubMed ID: 34882774
[TBL] [Abstract][Full Text] [Related]
17. Identification of an epithelial cell receptor responsible for Clostridium difficile TcdB-induced cytotoxicity.
LaFrance ME; Farrow MA; Chandrasekaran R; Sheng J; Rubin DH; Lacy DB
Proc Natl Acad Sci U S A; 2015 Jun; 112(22):7073-8. PubMed ID: 26038560
[TBL] [Abstract][Full Text] [Related]
18. Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab.
Hernandez LD; Kroh HK; Hsieh E; Yang X; Beaumont M; Sheth PR; DiNunzio E; Rutherford SA; Ohi MD; Ermakov G; Xiao L; Secore S; Karczewski J; Racine F; Mayhood T; Fischer P; Sher X; Gupta P; Lacy DB; Therien AG
J Mol Biol; 2017 Apr; 429(7):1030-1044. PubMed ID: 28232034
[TBL] [Abstract][Full Text] [Related]
19. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.
Davies NL; Compson JE; Mackenzie B; O'Dowd VL; Oxbrow AK; Heads JT; Turner A; Sarkar K; Dugdale SL; Jairaj M; Christodoulou L; Knight DE; Cross AS; Hervé KJ; Tyson KL; Hailu H; Doyle CB; Ellis M; Kriek M; Cox M; Page MJ; Moore AR; Lightwood DJ; Humphreys DP
Clin Vaccine Immunol; 2013 Mar; 20(3):377-90. PubMed ID: 23324518
[TBL] [Abstract][Full Text] [Related]
20. Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains.
Secore S; Wang S; Doughtry J; Xie J; Miezeiewski M; Rustandi RR; Horton M; Xoconostle R; Wang B; Lancaster C; Kristopeit A; Wang SC; Christanti S; Vitelli S; Gentile MP; Goerke A; Skinner J; Strable E; Thiriot DS; Bodmer JL; Heinrichs JH
PLoS One; 2017; 12(1):e0170640. PubMed ID: 28125650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
